Skip to content

Released Nov 9, 2021, before the open

10-Q filed Nov 9, 2021, 40 days after period end · 0001628280-21-022556

Q3 2021 · 10-Q
Revenue$41.00K−77.1% vs Q3 2020−85.3% vs Q2 2021
Net Income-$26.08MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.71N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$26,261,000N/M
Operating Cash Flowderived-$20,502,000N/M
Free Cash Flowderived-$20,732,000N/M
Margins · derived
Operating margin-64051.2%−53722.2 pt vs Q3 2020
Net margin-63609.8%−53348.9 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019
Revenue$41.00K$179.00K—
Net Income-$26.08M-$18.37M-$13.09M
EPS Diluted-$0.71-$3.12-$3.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR